Positive data from Phase III study of TA 7284 (Janssen Pharmaceuticals) for patients with Type 2 Diabetes

New results show that TA 7284 (canagliflozin), from Janssen Pharma, substantially lowers blood glucose levels compared to placebo when used as add-on therapy in patients with Type 2 Diabetes who are inadequately controlled with the antihyperglycemic medications metformin and pioglitazone. Results from the Phase III study (DIA3012) showed that canagliflozin, dosed once daily at 100 mg or 300 mg in addition to metformin and pioglitazone, had statistically greater A1C reductions at 26 weeks relative to placebo (change from baseline, -0.89% and -1.03%, vs. -0.26%, respectively, p<0.001). the overall incidence of adverse events aes was generally similar across all treatment arms.>

In secondary efficacy endpoint measures, both canagliflozin dose groups provided reductions in body weight compared to placebo and reductions in systolic blood pressure. These results were presented by Dr. Thomas Forst, lead investigator on the study from the University of Mainz in Mainz, Germany, at the 4th World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy).